XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
Rhea-AI Summary
XOMA Royalty (NASDAQ: XOMA) has successfully completed its tender offer to acquire Turnstone Biologics (NASDAQ: TSBX). The deal terms included $0.34 per share in cash plus one non-tradeable contingent value right (CVR).
As of the expiration date on August 7, 2025, 17,192,002 shares were validly tendered, representing approximately 74% of Turnstone's outstanding shares. Following the tender offer, XOMA Royalty merged Turnstone with its subsidiary XRA 3 Corp., making Turnstone a wholly owned subsidiary. Turnstone's shares will cease trading on Nasdaq as of August 11, 2025, and will be delisted and deregistered.
Positive
- None.
Negative
- Low per-share purchase price of $0.34 indicates potential challenges in Turnstone's business
- Delisting from Nasdaq reduces liquidity for remaining shareholders
News Market Reaction – XOMA
On the day this news was published, XOMA gained 2.75%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Turnstone Stockholders Received
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Turnstone Biologics Corp. (NASDAQ: TSBX) common stock for a price per share of
The tender offer and related withdrawal rights expired one minute after 11:59 p.m. Eastern Time on Thursday, August 7, 2025 (the “Expiration Date”). As of the Expiration Date, a total of 17,192,002 shares of Turnstone common stock were validly tendered, and not validly withdrawn, representing approximately
Following the closing of the tender offer, XOMA Royalty merged Turnstone with and into a subsidiary, XRA 3 Corp. (the “Merger”), and all shares of Turnstone common stock that had not been validly tendered were converted into the right to receive the Offer Price. As a result of the Merger, Turnstone became a wholly owned subsidiary of XOMA Royalty. Prior to the opening of trading on The Nasdaq Stock Market LLC (“Nasdaq”) on August 11, 2025, all shares of Turnstone common stock will cease trading on Nasdaq, and Turnstone intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.
Advisors
XOMA Royalty was represented by Gibson, Dunn & Crutcher LLP. Leerink Partners acted as the exclusive financial advisor and Cooley LLP acted as legal counsel to Turnstone.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about XOMA Royalty and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
Forward-Looking Statements/Explanatory Notes
Certain statements contained in this press release are forward-looking statements, including statements regarding the payment and timing of payment of the Offer Price to former Turnstone common stockholders and the ability and timing of delisting of Turnstone’s common stock. In some cases, you can identify such forward-looking statements by terminology such as “expect,” “may,” or “will,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA Royalty’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks including that XOMA Royalty does not achieve anticipated net cash after winding down Turnstone’s operations, that the timing of the payment or delisting may be delayed and that there are no payments made under the CVRs. Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty’s most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission (“SEC”). Any forward-looking statement in this press release represents XOMA Royalty’s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law.
EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.
| XOMA Royalty Investor Contact | XOMA Royalty Media Contact |
| Juliane Snowden XOMA Royalty Corporation +1 646-438-9754 juliane.snowden@xoma.com | Kathy Vincent KV Consulting & Management kathy@kathyvincent.com |
FAQ
How much did XOMA Royalty pay per share for Turnstone Biologics?
What percentage of Turnstone Biologics shares were tendered to XOMA?
When will Turnstone Biologics (TSBX) be delisted from Nasdaq?
Who were the advisors for the XOMA-Turnstone acquisition?
